Trade Humacyte, Inc. - HUMA CFD

Humacyte, Inc. Company profile

About Humacyte Inc

Humacyte, Inc. (Humacyte), formerly Alpha Healthcare Acquisition Corp., is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. The Company uses its technology platform to engineer and manufacture human acellular vessels (HAVs). The HAVs are designed to be implanted into any patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio (or cabinet) of HAVs with varying diameters and lengths. The HAV cabinet offers treatment solution in various clinical areas within vascular repair, reconstruction and replacement market, including trauma, AV access for hemodialysis, peripheral arterial disease (PAD), and coronary artery bypass grafting (CABG). In addition, the Company develops HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Humacyte Inc revenues increased from $0K to $1.1M. Net loss applicable to common stockholders increased from $19K to $69.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items totaled to -$1.91.